CellaVision sales jump 13.6% to SEK 200 million in third quarter
Key Facts
CellaVision lifted net sales 13.6% year on year to 200 million Swedish kronor in the third quarter of 2026, compared with 176 million in the same period of 2025, according to its interim results. Organic growth was 13.4%, after growth of 2.6% in the comparative period. The results showed a simultaneous improvement in earnings and operating cash flow. The company said, "Net sales increased 13.6% to 200 million Swedish kronor." The figures cover July to September and therefore do not represent full-year sales. No available source confirmed that the share rose 4% after the announcement, so the published results do not confirm a share-price move.
Revenue growth was reflected in profitability indicators, with profit before tax rising to 51 million Swedish kronor in the third quarter from 39 million a year earlier. Earnings per share, both basic and diluted, increased to 1.68 kronor from 1.31 kronor in the comparative period, according to the interim report. EBITDA also rose to 64 million kronor from 50 million. The EBITDA margin widened to 32% from 28%. The company said, "The EBITDA margin rose to 32%." These comparisons show earnings and margin improvements alongside higher sales during the quarter.
Cash flow from operating activities was 68 million Swedish kronor in the third quarter, up from 30 million in the corresponding quarter of 2025. CellaVision said operating cash flow "increased to 68 million Swedish kronor." This completes the picture of quarterly results, which included growth in sales and earnings as well as an increase in cash generated by operating activities. Sales had fallen 1.7% in the comparative quarter, according to the figure in parentheses in the sales statement, before returning to growth in the current period. By contrast, organic business growth was 13.4% in the third quarter, compared with organic growth of 2.6% in the comparative period. These indicators place the current quarter's performance in the context of a period that saw a slight contraction in total sales and slower organic growth.
For the full year, the company's sales were 759 million Swedish kronor in 2025, while its stated ambition is annual growth of 15% over an economic cycle. This target provides a framework for comparison with quarterly sales growth, but applies to a full economic cycle and does not change the fact that the reported 13.6% increase relates to the third quarter alone. The company repeated its 2025 sales figure and the same target in its results announcement and annual and sustainability report. It said in the report, "The company's target is growth of 15% annually over an economic cycle." Placing the annual figure alongside the quarter's performance distinguishes the company's longer-term target from the result recorded over three months. The available information did not include an update to this target in the quarterly results announcement.
CellaVision set a later date to present its updated strategic direction and priorities through 2030, at a capital markets day in Stockholm on February 17, 2027. The company said its executive management would present the "updated strategic direction and priorities through 2030" at the event. The date comes after the third-quarter results and gives the company an opportunity to present its plans and priorities for the coming period to capital markets. The announcement points to a strategic horizon through 2030, while setting the event date in 2027. The quarterly results did not provide further details on the updated direction or its expected effect on sales. The upcoming event remains the next announced date for management to present its priorities over this time horizon.